du Bois A, Baert T, Vergote I. Role of neoadjuvant chemotherapy in advanced epithelial ovarian cancer. J Clin Oncol. 2019;37:2398–405.
Google Scholar
Vergote I, Coens C, Nankivell M, Kristensen GB, Parmar MKB, Ehlen T, et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncol. 2018;19:1680–87.
Google Scholar
Previs RA, Secord AA. Ovarian cancer: clinical trial breakthroughs and impact on management. Obstet Gynecol Clin North Am. 2019;46:67–88.
Google Scholar
Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943–53.
Google Scholar
Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34:3460–73.
Google Scholar
Bregar A, Mojtahed A, Kilcoyne A, Kurra V, Melamed A, Growdon W, et al. CT prediction of surgical outcome in patients with advanced epithelial ovarian carcinoma undergoing neoadjuvant chemotherapy. Gynecol Oncol. 2019;152:568–73.
Google Scholar
Vergote I, du Bois A, Amant F, Heitz F, Leunen K, Harter P. Neoadjuvant chemotherapy in advanced ovarian cancer: on what do we agree and disagree? Gynecol Oncol. 2013;128:6–11.
Google Scholar
Fagotti A, Fanfani F, Vizzielli G, Gallotta V, Ercoli A, Paglia A, et al. Should laparoscopy be included in the work-up of advanced ovarian cancer patients attempting interval debulking surgery? Gynecol Oncol. 2010;116:72–7.
Google Scholar
Lv X, Cui S, Zhang X, Ren C. Efficacy and safety of neoadjuvant chemotherapy versus primary debulking surgery in patients with ovarian cancer: a meta-analysis. J Gynecol Oncol. 2020;31:e12.
Google Scholar
Lee EYP, Ip PPC, Tse KY, Chiu KWH, Chu MMY, Chai YK, et al. Prospective validation of the role of PET/CT in detecting disease after neoadjuvant chemotherapy in advanced ovarian cancer. Eur Radiol. 2024;34:5911–22.
Google Scholar
Michielsen K, Vergote I, Op de Beeck K, Amant F, Leunen K, Moerman P, et al. Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT. Eur Radiol. 2014;24:889–901.
Google Scholar
Li C, Cui Q, Wang X, Yao S, Tu H, Chen M. CA-125 elimination rate constant K (KELIM) as a promising predictor of complete cytoreduction after neoadjuvant chemotherapy in advanced ovarian cancer patients: a retrospective study from two Chinese hospitals. BMC Cancer. 2024;24:609.
Google Scholar
Matsukuma K, Nishio S, Tasaki S, Park J, Nasu H, Yoshimitsu T, et al. Association of chemotherapy response score with multidrug resistance 1 and CA125 elimination rate constant K in patients with advanced ovarian cancer treated with neoadjuvant chemotherapy. Kurume Med J. 2024;70:29–37.
Google Scholar
Bouvarel B, Colomban O, Frenel JS, Loaec C, Bourgin C, Berton D, et al. Clinical impact of CA-125 ELIMination rate constant K (KELIM) on surgical strategy in advanced serous ovarian cancer patients. Int J Gynecol Cancer. 2024;34:574–80.
Google Scholar
Ducoulombier S, Golfier F, Colomban O, Benayoun D, Bolze PA, Tod M, et al. Modeling CA-125 during neoadjuvant chemotherapy for predicting optimal cytoreduction and relapse risk in ovarian cancer. Anticancer Res. 2017;37:6879–86.
Google Scholar
Pinto P, Burgetova A, Cibula D, Haldorsen IS, Indrielle-Kelly T, Fischerova D. Prediction of surgical outcome in advanced ovarian cancer by imaging and laparoscopy: a narrative review. Cancers. 2023;15:1904.
Google Scholar
Ledermann JA, Matias-Guiu X, Amant F, Concin N, Davidson B, Fotopoulou C, et al. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease. Ann Oncol. 2024;35:248–66.
Google Scholar
Dong L, Li K, Peng T. Diagnostic value of diffusion-weighted imaging/magnetic resonance imaging for peritoneal metastasis from malignant tumor: a systematic review and meta-analysis. Medicine. 2021;100:e24251.
Google Scholar
Meucci R, Prosperi D, Lauri C, Campagna G, Nayak P, Garaci F, et al. Peritoneal carcinomatosis of malignant gynecological origin: a systematic review of imaging assessment. J Clin Med. 2024;13:1254.
Google Scholar
Dumont S, Vandecaveye V, Dresen RC, Van Nieuwenhuysen E, Baert T, Amant F, et al. Predicting resectable disease in relapsed epithelial ovarian cancer by using whole-body diffusion-weighted MRI. Int J Gynecol Cancer. 2023;33:1890–97.
Google Scholar
Rizzo S, De Piano F, Buscarino V, Pagan E, Bagnardi V, Zanagnolo V, et al. Pre-operative evaluation of epithelial ovarian cancer patients: role of whole body diffusion weighted imaging MR and CT scans in the selection of patients suitable for primary debulking surgery. A single-centre study. Eur J Radiol. 2020;123:108786.
Google Scholar
Garcia Prado J, González Hernando C, Varillas Delgado D, Saiz Martínez R, Bhosale P, Blazquez Sanchez J, et al. Diffusion-weighted magnetic resonance imaging in peritoneal carcinomatosis from suspected ovarian cancer: diagnostic performance in correlation with surgical findings. Eur J Radiol. 2019;121:108696.
Google Scholar
Michielsen K, Dresen R, Vanslembrouck R, De Keyzer F, Amant F, Mussen E, et al. Diagnostic value of whole body diffusion-weighted MRI compared to computed tomography for pre-operative assessment of patients suspected for ovarian cancer. Eur J Cancer. 2017;83:88–98.
Google Scholar
Vergote IV, Van Nieuwenhuysen E, Vanderstichele A. How to select neoadjuvant chemotherapy or primary debulking surgery in patients with stage IIIC or IV ovarian carcinoma. J Clin Oncol. 2016;34:3827–28.
Google Scholar
Ramspott JP, Baert T, MacKintosh ML, Traut A, Ataseven B, Bommert M, et al. Response evaluation after neoadjuvant therapy: evaluation of chemotherapy response score and serological and/or radiological assessment of response in ovarian cancer patients. Arch Gynecol Obstet. 2021;304:1021–32.
Google Scholar
Pinto P, Moro F, Alcázar JL, Alessi S, Avesani G, Benesova K, et al. Prediction of non-resectability in tubo-ovarian cancer patients using Peritoneal Cancer Index – a prospective multicentric study using imaging (ISAAC study). Gynecol Oncol. 2024;191:132–42.
Google Scholar
Tsili AC, Alexiou G, Tzoumpa M, Siempis T, Argyropoulou MI. Imaging of peritoneal metastases in ovarian cancer using MDCT, MRI, and FDG PET/CT: a systematic review and meta-analysis. Cancers. 2024;16:1467.
Google Scholar
Engbersen MP, Van’ T Sant I, Lok C, Lambregts DMJ, Sonke GS, Beets-Tan RGH, et al. MRI with diffusion-weighted imaging to predict feasibility of complete cytoreduction with the peritoneal cancer index (PCI) in advanced stage ovarian cancer patients. Eur J Radiol. 2019;114:146–51.
Google Scholar
Michielsen KL, Vergote I, Dresen R, Op de Beeck K, Vanslembrouck R, Amant F, et al. Whole-body diffusion-weighted magnetic resonance imaging in the diagnosis of recurrent ovarian cancer: a clinical feasibility study. Br J Radiol. 2016;89:20160468.
Google Scholar
Rijsemus CJV, Kok NFM, Aalbers AGJ, Buffart TE, Fijneman RJA, Snaebjornsson P, et al. Diagnostic performance of MRI for staging peritoneal metastases in patients with colorectal cancer after neoadjuvant chemotherapy. Eur J Radiol. 2022;149:110225.
Google Scholar
Jónsdóttir B, Ripoll MA, Bergman A, Silins I, Poromaa IS, Ahlström H, et al. Validation of 18F-FDG PET/MRI and diffusion-weighted MRI for estimating the extent of peritoneal carcinomatosis in ovarian and endometrial cancer -a pilot study. Cancer Imaging. 2021;21:34.
Google Scholar
Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol. 2007;188:1622e35.
Google Scholar
Winfield JM, Wakefield JC, Brenton JD, AbdulJabbar K, Savio A, Freeman S, et al. Biomarkers for site-specific response to neoadjuvant chemotherapy in epithelial ovarian cancer: relating MRI changes to tumour cell load and necrosis. Br J Cancer. 2021;124:1130–37.
Google Scholar
Zugni F, Mariani L, Lambregts DMJ, Maggioni R, Summers PE, Granata V, et al. Whole-body MRI in oncology: acquisition protocols, current guidelines, and beyond. Radiol Med. 2024;129:1352–68.
Google Scholar
Leone Roberti Maggiore U, Bogani G, Martinelli F, Signorelli M, Chiappa V, Lopez S, et al. Response to treatment and prognostic significance of supradiaphragmatic disease in patients with high-grade serous ovarian cancer. Eur J Surg Oncol. 2022;48:2551–57.
Google Scholar
Eskander RN, Kauderer J, Tewari KS, Mannel RS, Bristow RE, O’Malley DM, et al. Correlation between Surgeon’s assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2018;149:525–30.
Google Scholar
Vandecaveye V, Rousset P, Nougaret S, Stepanyan A, Otero-Garcia M, Nikolić O, et al. European Society of Gastrointestinal and Abdominal Radiology (ESGAR); European Society of Urogenital Radiology (ESUR); Peritoneal Surface Oncology Group International (PSOGI); European Association of Nuclear Medicine (EANM). Imaging of peritoneal metastases of ovarian and colorectal cancer: joint recommendations of ESGAR, ESUR, PSOGI, and EANM. Eur Radiol. 2025;35:2712–22.
Google Scholar
Lambregts DMJ, van Heeswijk MM, Delli Pizzi A, van Elderen SGC, Andrade L, Peters N, et al. Diffusion-weighted MRI to assess response to chemoradiotherapy in rectal cancer: main interpretation pitfalls and their use for teaching. Eur Radiol. 2017;27:4445–54.
Google Scholar
Vandecaveye V, Dresen RC, Broeckhoven V, Baert T, Van Nieuwenhuysen E, Dekeyzer F, et al. Predictive value of whole-body diffusion-weighted MRI in the preoperative assessment of advanced ovarian cancer after neo-adjuvant chemotherapy. Int J Gynecol Cancer. 2024;34:A364.
Vandecaveye V, Dresen RC, Broeckhoven V, Baert T, Van Nieuwenhuysen E, Dekeyzer F, et al. Predictive value of whole-body diffusion-weighted MRI in the preoperative assessment of advanced ovarian cancer after neo-adjuvant chemotherapy. Abstract Archives of the RSNA. 2024;T3-SSOB02-5.
